Corrigendum to “Evaluation of the potential impact and cost-effectiveness of respiratory syncytial virus (RSV) prevention strategies for infants in Argentina” [Vaccine. Volume 42, Issue 23, 3 October 2024, 126234]

The authors regret < We have found some typos in the online publication, and we would kindly like to ask you to correct them.

1 Abstract – “Either strategy (RSV mAb or maternal RSV vaccine) could prevent >25% of RSV deaths aged <5 years and ∼30% aged <6 months (the age group where most intervention impact occurs).” should be “Either strategy (RSV mAb or maternal RSV vaccine) could prevent >25% of RSV deaths aged <5 years and >50% of RSV deaths aged <6 months (the age group where most intervention impact occurs).”

2 Section 3.1 - “Both strategies were estimated to prevent >25% of RSV deaths in children aged under 5 years, and ∼ 30% in children aged <6 months” should be “Both strategies were estimated to prevent >25% of RSV deaths in children aged under 5 years, and >50% of RSV deaths in children aged <6 months”.

3 In table 1 “Price per dose” is showing $3.30 should be $50>.

The authors would like to apologise for any inconvenience caused.